Exactly, notice how these so-called "experts" starting writing this stuff when the price starts going up a buck from where we were last week. Typical. And there will be a lot of these efforts to cause panic by the Shorts. I am sure Adam #$%$......stein is working feverishly on one right now.
Hey diejour, Are you long here too or are you just looking into it? I don't know enough about Oramed but I do know as you do that phase 2 is a long way off. Also mnkd will be tough to beat due to the ultra rapid onset and exit of Afrezza's effect. This results in the huge benefit of significantly less hypos which allows one to titrate up and safely push sugars lower. Also Technosphere has huge licensing potential.
sharon says,"Oramed has successfully designed a compound that resists inactivation during digestion and delivers a full therapeutic dose across the intestinal wall with all its components intact; this is elegantly done with known materials that do not need a separate FDA nod as new chemical entities. These ingredient adjuvants, or helpers, protect the oral capsules' contents and are engineered to release them into the body's general circulation where they make their way into the liver through the hepatic portal vein"
first off how does this work at meal time?? right, it doesn't. second comment is the "adjuvent" good luck with that too..............fda hates adjuvents.........look at dvax.JMHO
If you review Oramed's web site, and their own list of clinical trials to date, they have been running P2 clinical trials since 2008. Again, they are starting another P2 trial after having already completed four P2 trials. So they seem to be stuck at the P2 trial phase. This company is a long, long way from producing anything on a commercial basis if they ever do.
Plus if you read Oramed's own website regarding their oral insulin product, quote: "Oramed proposes to introduce ORMD-0801 treatment as a complementary agent to insulin injections in the treatment of T1DM." So their product is used in combination with other insulin products, not in place of insulin products such as Afrezza.
Absolutely not. They got approval for Phase II trial based on 8 patients. 8 patients! and positive results on 6 of 8 patients. You don't need a good drug to get positive results from 6 patients. You just need a good clinical trial person to select 6 patients that would have gotten better with the slightest medication given. Ask me again after they complete Phase II.
BTW, if you look at their website, their CEO is a lawyer. How would you like to invest in a premier research firm where their lead scientist is a doctor in law?